Prior to his new role, Dr. Hollander served as chief research and development officer at Aerie Pharmaceutical. Dr. Hollander has 20 years of experience in the biotech and pharmaceutical industry, according to the Oct. 17 Revance news release.
“David joins Revance at an exciting time, as we turn our sights towards aesthetics commercial launch, international regulatory strategy, and the advancement of our therapeutics opportunity and biosimilar to Botox program,” Revance President Dustin Sjuts said. “With his proven leadership and extensive background and experience leading global clinical development, regulatory strategies and product life-cycle management, David will augment our capabilities in these areas to support our growth in the years ahead.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
